| Name | Title | Contact Details |
|---|
For over 100 years the name Viking has represented global leadership in fire protection. We lead the industry in quality and innovation because fire protection is all we do, and our single focus is to support and enhance the efforts of independent fire sprinkler contractors. We believe that protecting people and property from fire transcends the bottom line, and we never stop asking "what do our customers need to be successful?" Today, The Viking Group provides independent fire sprinkler contractors with integrated solutions for any fire protection challenge. Rely on Viking to deliver: Unmatched Quality: Our reputation has been earned by focusing on continuous improvement in all elements of our business – from the products we manufacture to the services we provide. Product Breadth: The largest selection of fixed fire protection products and services ensures single-point solutions for any fire protection challenge. Experienced Support: Knowledgeable customer service and technical support at every point in the project process. Innovation that Matters: From valves that are easier to install and maintain, to automated fabrication capabilities, Viking innovates to solve problems and strengthen your business. Everywhere You Need Us: With our global network of independent distribution partners and dozens of locations, Vikings products and services are available when and where you need them.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
Integrity is the nations leading distributor of life and health insurance, and provider of innovative solutions for wealth management and retirement planning.
Syensqo is a leading science company whose ground-breaking technologies revolutionize the way we live. Our purpose is to advance human progress while cultivating a future for our planet that is not only safer and cleaner, but also inherently more sustainable, driven by the principles of circular economy. Our disruptive, market-leading solutions address fundamental megatrends. We play a key role in the future of clean mobility and bring about breakthroughs in biotechnology, natural ingredients, and circular solutions, contributing to sustainable, high-performance products for homes, food and consumer goods, planes, cars, smart devices, and healthcare applications. Inspired by the scientific councils, which Ernest Solvay initiated in 1911, we bring great minds together to push the limits of science and innovation for the benefit of our customers, with a diverse, global team of more than 13,000 associates in 30 countries.